A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 06 Nov 2017 Planned End Date changed from 14 Nov 2018 to 9 Jan 2019.
- 06 Nov 2017 Planned initiation date changed from 1 Dec 2017 to 26 Jan 2018.
- 20 Jul 2017 New trial record